natgillin/translations-raw huggingface dataset:
For schizophrenia, the recommended starting dose is 10 or 15 mg by mouth per day in adults, followed by a ‘maintenance' dose of 15 mg once a day. 
U slučaju shizofrenije preporučena početna doza iznosi 10 ili 15 mg peroralno na dan za odrasle osobe, nakon čega slijedi doza "održavanja" od 15 mg jednom na dan.
Other information about Aripiprazole Sandoz 
Ostale informacije o lijeku Aripiprazole Sandoz
Aripiprazole Sandoz contains the active substance aripiprazole and is a ‘generic' and a ‘hybrid' medicine. 
Sandoz sadrži djelatnu tvar aripiprazol te je "generički" i "hibridni" lijek.
For treating manic episodes in patients aged between 13 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day. 
Za potrebe liječenja maničnih epizoda u bolesnika u dobi između 13 i 17 godina, početna doza iznosi 2 mg na dan (primjenom lijeka koji sadrži aripiprazol dostupnog u tekućem obliku), koji se postepeno povećava do preporučene doze od 10 mg jednom na dan.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Aripiprazole Sandoz has been shown to have comparable quality and to be bioequivalent to Abilify. 
Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) pri Agenciji zaključilo je kako je, u skladu s preduvjetima EU-a, potvrđeno kako Aripiprazole
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Aripiprazole Sandoz, including the appropriate precautions to be followed by healthcare professionals and patients. 
Sandoz uključene su sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
The full EPAR and risk management plan summary for Aripiprazole Sandoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Sandoz nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Više informacija o terapiji lijekom Aripiprazole Sandoz pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
For practical information about using Aripiprazole Sandoz, patients should read the package leaflet or contact their doctor or pharmacist. 
Sandoz pročitajte u uputi o lijeku, odnosno obratite se svojem liječniku ili ljekarniku.
How is Aripiprazole Sandoz used? 
Kako se koristi Aripiprazole Sandoz?
How does Aripiprazole Sandoz work? 
Kako djeluje Aripiprazole Sandoz?
The company carried out ‘bioequivalence' studies to show that Aripiprazole Sandoz is bioequivalent to the reference medicine, Abilify. 
Tvrtka je provela ispitivanja "bioekvivaletnosti" kako bi dokazala da je Aripiprazole
Why is Aripiprazole Sandoz approved? 
Sandoz odobren?
Then carry on as normal, sticking to your usual injection day. 
Zatim nastavite po normalnom rasporedu, pridržavajući se svog uobičajenog dana injekcije.
If you experience any of the following, contact your doctor immediately: 
Ako primijetite bilo što od sljedećeg, odmah se obratite svom liječniku:
Daclizumab beta pharmacokinetics are well described by a two-compartment model with first-order absorption and elimination. 
Farmakokinetika daklizumaba beta dobro je opisana modelom s dva odjeljka s apsorpcijom i eliminacijom prvog reda.
(Uncommon - may affect up to 1 in 100 people) • Severe inflammation of the liver which might be life-threatening or result in death 
(Manje često - mogu se javiti u manje od 1 na 100 osoba) • teška upala jetre koja može biti opasna za život ili imati za posljedicu smrtni ishod
Daclizumab beta had no effect on peri- and post-natal development from birth to up to 6 months in the offspring. 
Daklizumab beta nije imao utjecaja na peri- i postnatalni razvoj mladunčadi od rođenja do 6 mjeseci života.
Do not share the pen with anyone else to avoid giving an infection to them or getting an 
Nemojte dijeliti brizgalicu ni s kim drugim kako bi se izbjeglo da svoju infekciju prenesete na druge ili da se infekcija s drugih prenese na Vas.
Table 3: Study design and baseline characteristics for SELECT study and DECIDE study Study name 
Tablica 3: Dizajn ispitivanja i početne značajke ispitivanja SELECT i DECIDE Naziv ispitivanja
Chronic administration of daclizumab beta at all doses increased the incidence of skin findings (compared to those observed in control animals). 
Kronična primjena daklizumaba beta pri svim dozama povećala je incidenciju nalaza na koži (u odnosu na one opažene kod kontrolnih životinja).
Four new serious cases of colitis confirmed by health-care professionals have been received during this period. 
Tijekom ovoga razdoblja prijavljena su četiri nova ozbiljna slučaja kolitisa koja su potvrdili zdravstveni radnici.
In the DECIDE study (see section 5.1), patients were tested for anti-drug (daclizumab beta) antibodies at week 4 and approximately every 3 months thereafter. 
U ispitivanju DECIDE (vidjeti dio 5.1), bolesnici su testirani na protutijela na lijek (daklizumab beta) u 4. tjednu i otprilike svaka 3 mjeseca nakon toga.
• Recommended storage is controlled refrigeration 2°C to 8°C in the closed original carton to 
• Preporučeno čuvanje je kontrolirano rashlađivanje od 2°C do 8°C u zatvorenoj originalnoj kutiji radi zaštite od svjetlosti.
Do not try to treat any side effects yourself, but contact your doctor or nurse. 
Nemojte pokušati sami liječiti nijednu nuspojavu, nego se obratite svom liječniku ili medicinskoj sestri.
Low red blood cell counts (autoimmune haemolytic anaemia): (Uncommon - may affect up to 1 in 100 people) 
Nizak broj crvenih krvnih stanica (autoimuna hemolitična anemija): (Manje često - mogu se javiti u manje od 1 na 100 osoba)
Using one hand, hold the syringe by the glass barrel. 
Jednom rukom držite štrcaljku za stakleni cilindar.
Daclizumab beta was detected in the milk of 11/14 lactating monkeys at levels that were <0.122% of the maternal serum levels, with no adverse reactions observed in the off-spring. 
Daklizumab beta je otkriven u mlijeku 11/14 ženki majmuna u laktaciji na razinama koje su bile <0,122% od razina u serumu majke, bez nuspojava opaženih u mladunčadi.
Step 4: Firmly remove the needle cover 
4. korak: Snažnim pokretom uklonite pokrov igle
In vitro investigative studies suggest that microglial aggregates are not due to a direct effect of daclizumab beta on microglial cells but are likely to be attributable to an increase in local IL-2 bioavailability. 
In vitro istražna ispitivanja upućuju na to da agregati mikroglije nisu posljedica izravnog učinka daklizumaba beta na stanice mikroglije, nego su vjerojatno posljedica povećanja lokalne bioraspoloživosti IL-2.
Daclizumab beta did not affect reproductive capacity in female and male cynomolgus monkeys (AUC in females and males up to 85 and 100 times higher than the exposure at the clinical dose respectively). 
Daklizumab beta nije utjecao na reproduktivni kapacitet ženki i mužjaka makaki majmuna (AUC u ženki i mužjaka do 85 odnosno 100 puta veći od izloženosti pri kliničkoj dozi).
Based on the cross-study population pharmacokinetic analysis, daclizumab beta pharmacokinetics were not influenced by age (range: 18 to 66 years; n=1670) or gender (n = 567 males and 1103 females). 
Na temelju analize populacijske farmakokinetike između ispitivanja, na farmakokinetiku daklizumaba beta nisu utjecali dob (raspon: 18 do 66 godina; n=1670) niti spol (n = 567 muškaraca i 1103 žena).
Do not use Zinbryta - if you have previously had a serious allergic reaction to any form of daclizumab, or any of the other ingredients of this medicine listed in section 6. 
Nemojte primjenjivati Zinbrytu - ako ste imali ozbiljnu alergijsku reakciju na bilo koji oblik daklizumaba ili neki drugi sastojak ovog lijeka naveden u dijelu 6. - ako imate tegobe s jetrom.
Available toxicology data in lactating cynomolgus monkeys have shown excretion of daclizumab beta in milk (for details see section 5.3). 
Dostupni toksikološki podaci u makaki majmuna u laktaciji pokazali su izlučivanje daklizumaba beta u mlijeko (za detalje vidjeti dio 5.3).
This small volume of distribution indicates that daclizumab beta is primarily confined to the vascular and interstitial spaces. 
Taj mali volumen distribucije pokazuje da je daklizumab beta prvenstveno ograničen na krvožilni i intersticijski prostor.
Check the medicine window and make sure the Zinbryta medicine is colourless to 
Provjerite prozorčić za lijek i provjerite je li lijek Zinbryta bezbojan do blago žut.
Following subcutaneous administration of daclizumab beta, the median time to reach maximum serum concentrations (Tmax) ranged from 5 to 7 days. 
Nakon supkutane primjene daklizumaba beta, medijan vremena do postizanja maksimalne koncentracije u serumu (Tmax) kretao se u rasponu od 5 do 7 dana.
• Patients with 2 or more relapses in 1 year, and with 1 or more Gd-enhancing lesions on brain 
• Bolesnici s 2 ili više relapsa u 1 godini, i s 1 ili više lezija imbibiranih gadolinijem na MR snimci mozga, ili
Preclinical safety studies were conducted in cynomolgus monkeys due to species specificity of daclizumab beta binding only to human or primate CD25. 
Neklinička ispitivanja sigurnosti su provedena u makaki majmuna zbog specifičnosti vezanja daklizumaba beta samo na ljudski ili primatski CD25.
• If you do forget a dose, and it is within 2 weeks of your missed dose, inject as soon as you can. 
• Ako zaboravite primijeniti dozu, a prošlo je manje od 2 tjedna od propuštene doze, injicirajte je čim prije možete.
• The recommendation not to initiate treatment in patients with autoimmune disorders (other than 
• preporuku da ne započinju liječenje u bolesnika s autoimunim poremećajima (osim multiple skleroze)
It should include the following elements: 
Obrazac mora uključivati sljedeće:
There was no apparent correlation of anti-drug antibodies or neutralising antibodies development to clinical response, adverse reactions, or pharmacodynamic profile of daclizumab beta. 
Nije bilo vidljive korelacije između razvoja protutijela na lijek ili neutralizirajućih protutijela i kliničkog odgovora, nuspojava ili farmakodinamičkog profila daklizumaba beta.
No risk factors or alternative aetiology have been reported in any of these cases. 
Ni u jednom od tih slučajeva nisu zabilježeni čimbenici rizika ili neka druga etiologija.
Consistent with results from individual studies, a cross-study population pharmacokinetic analysis indicated that daclizumab beta exposure is more than dose-proportional in the 50 mg to 100 mg subcutaneous dose range and is dose proportional in the 100 mg to 300 mg subcutaneous dose range. 
U skladu s rezultatima iz pojedinačnih ispitivanja, analiza populacijske farmakokinetike između ispitivanja pokazala je da je izloženost daklizumabu beta više nego proporcionalna dozi u rasponu supkutanih doza od 50 mg do 100 mg, a proporcionalna je dozi u rasponu supkutanih doza od 100 mg do 300 mg.
Daclizumab beta is produced in a mammalian cell line (NS0) by recombinant DNA technology. 
Daklizumab beta je proizveden tehnologijom rekombinantne DNK u staničnoj liniji sisavaca (NS0).
These findings (dry, red raised patchy areas of the skin, as compared to controls, that correlated microscopically with acanthosis/hyperkeratosis and subacute to chronic inflammation) were characterised predominantly as mild to moderate, with one case assessed as severe. 
Ti nalazi (suhe, crvene uzdignute mrlje na koži, u usporedbi s kontrolama, koje koreliraju mikroskopski s akantozom/hiperkeratozom i subakutnim do kroničnim upalama) uglavnom su karakterizirani kao blagi do umjereni, s jednim slučajem ocijenjenim kao teškim.
Together, these immunomodulatory effects of daclizumab beta are believed to reduce CNS pathology in MS and thereby reduce the occurrence of relapses and disability progression. 
Smatra se da ovi imunomodulirajući učinci daklizumaba beta zajedno smanjuju patologiju SŽS-a u MS-u te time smanjuju pojavu relapsa i napredovanja onesposobljenosti.
Do not inject into an area of your body where the skin is irritated, red, bruised, tattooed, infected, or scarred. 
Nemojte injicirati u područja na kojima je koža nadražena, crvena, s modricama, tetovirana, zaražena ili s ožiljcima.
Key effects of this IL-2 pathway modulation potentially related to the therapeutic effects of daclizumab beta in MS include selective antagonism of activated T-cell responses, and expansion of immunoregulatory CD56bright natural killer (NK) cells, which have been shown to selectively decrease activated T-cells. 
Ključni učinci ove modulacije signalnog puta IL-2 potencijalno povezani s terapijskim učincima daklizumaba beta u multiploj sklerozi uključuju selektivni antagonizam odgovora aktiviranih T-stanica i ekspanziju imunoregulatornih CD56bright stanica prirodnih ubojica (NK), za koje je pokazano da selektivno smanjuju broj aktiviranih T-stanica.
• The need to screen for hepatitis B and C prior to treatment initiation and to recommend patients who test positive for HBV or HCV infection to consult with a physician with expertise in the 
• potrebu testova na hepatitis B i C prije početka liječenja i potrebu da se bolesnicima koji su pozitivni na infekciju HBV-om ili HCV-om preporuči zatražiti savjet liječnika specijalista za liječenje tih bolesti
The absolute bioavailability of daclizumab beta 150 mg subcutaneously administered was approximately 90% based on a cross-study population pharmacokinetic analysis of subcutaneous and intravenous dosing. 
Apsolutna bioraspoloživost supkutano primijenjenog daklizumaba beta od 150 mg bila je otprilike 90% na osnovi analize populacijske farmakokinetike između ispitivanja supkutanog i intravenskog doziranja.
As an IgG1 monoclonal antibody, daclizumab beta is expected to undergo catabolism to peptides and amino acids in the same manner as endogenous IgG. 
Budući da je IgG1 monoklonsko protutijelo, za daklizumab beta se očekuje katabolizam na peptide i aminokiseline na isti način kao i za endogeni IgG.
Twelve cases of sarcoidosis confirmed by health-care professionals were reported from clinical trials cumulatively. 
Iz kliničkih ispitivanja kumulativno je prijavljeno dvanaest slučajeva sarkoidoze koje su potvrdili zdravstveni radnici.
Potential adverse reactions beyond this level are expected to be consistent with the safety profile for daclizumab beta in MS patients. 
Očekuje se da će potencijalne nuspojave iznad te razine biti u skladu sa sigurnosnim profilom za daklizumab beta u bolesnika s MS-om.
Based on the cross-study population pharmacokinetic analysis, the clearance of daclizumab beta is 0.212 L/day with a terminal half-life value of approximately 21 days. 
Na temelju analize populacijske farmakokinetike između ispitivanja, klirens daklizumaba beta iznosi 0,212 l/dan s vrijednošću terminalnog poluvijeka od oko 21 dana.
- at least monthly blood tests during treatment, as close as possible before each dose of Zinbryta, and more often if your doctor decides this is necessary - tests for up to 6 months after stopping treatment. 
- najmanje jednom mjesečno testiranje krvi tijekom liječenja, i to što bliže prije primjene svake doze Zinbryte, a češće ako liječnik odluči da je to potrebno - testiranje do 6 mjeseci nakon prestanka liječenja.
Based on the cross-study population pharmacokinetic analysis, the steady-state volume of distribution of daclizumab beta is 6.34 L in a patient with a body weight of 68 kg (approximate median of evaluated patients). 
Na temelju analize populacijske farmakokinetike između ispitivanja, volumen distribucije daklizumaba beta u stanju dinamičke ravnoteže je 6,34 l u bolesnika s tjelesnom težinom od 68 kg (približan medijan procijenjenih bolesnika).
Daclizumab beta is a humanised IgG1 monoclonal antibody that binds to CD25 (IL-2Rα), and prevents IL-2 binding to CD25. 
Daklizumab beta je humanizirano IgG1 monoklonsko protutijelo koje se veže na CD25 (IL-2Rα), te sprječava vezanje IL-2 na CD25.
• You do not see the green stripes in the 
• ne vidite zelene trake u prozorčiću stanja
Based on the cross-study population pharmacokinetic analysis, body weight accounted for less than 40% of the inter-patient variability in daclizumab beta clearance. 
Na temelju analize populacijske farmakokinetike između ispitivanja, tjelesna težina bila je uzrok za manje od 40% varijabilnosti između bolesnika u klirensu daklizumaba beta.
On the basis of the scientific conclusions for daclizumab beta the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing daclizumab beta is unchanged subject to the proposed changes to the product information 
Na temelju znanstvenih zaključaka za daklizumab beta, CHMP smatra da je omjer koristi i rizika lijeka(ova) koji sadrži(e) daklizumab beta nepromijenjen, uz predložene izmjene informacija o lijeku.
Do not inject directly into your belly 
Nemojte injicirati izravno u pupak.
• Immune disorder that can affect the lungs, skin and lymph nodes (sarcoidosis) 
• poremećaj imunološkog sustava koji može zahvatiti pluća, kožu i limfne čvorove (sarkoidoza)
Daclizumab beta clearance in patients who developed neutralising antibodies was, on average, 19% higher (see section 4.8 Immunogenicity). 
Klirens daklizumaba beta u bolesnika koji su razvili neutralizirajuća protutijela bio je u prosjeku 19% viši (vidjeti dio 4.8
In two 9 month studies conducted in cynomolgus monkeys daclizumab beta was subcutaneously administered at bi-weekly doses of 10-200 mg/kg. 
U dva 9-mjesečna ispitivanja provedena u makaki majmuna, daklizumab beta je primijenjen supkutano u dvotjednim dozama od 10-200 mg/kg.
Zinbryta is contraindicated in patients with a history of severe hypersensitivity (e.g. anaphylaxis or anaphylactoid reactions) to all forms of daclizumab or to any of the excipients in Zinbryta (see section 
Zinbryta je kontraindicirana u bolesnika s anamnezom teške preosjetljivosti (npr. anafilaksija ili anafilaktoidna rekcija) na sve oblike daklizumaba ili na neku od pomoćnih tvari u Zinbryti (vidjeti dio
• If some areas are too difficult for you to reach, ask a carer who has been trained to 
• Ako Vam je teško doprijeti do nekih područja, zamolite za pomoć njegovatelja koji je prošao obuku kako bi Vam mogao pomoći.
Daclizumab beta modulates IL-2 signalling by blocking CD25dependent, high-affinity IL-2 receptor signalling, resulting in higher levels of IL-2 available for signalling through the intermediate-affinity IL-2 receptor. 
Daklizumab beta modulira signaliziranje IL-2 blokiranjem signaliziranja putem receptora visokog afiniteta za IL-2 ovisnog o CD25, što dovodi do viših razina IL-2 na raspolaganju za signaliziranje putem receptora intermedijarnog afiniteta za IL-2.
No studies were conducted to evaluate daclizumab beta pharmacokinetics in patients with renal or hepatic impairment. 
Nisu provedena ispitivanja za procjenu farmakokinetike daklizumaba beta u bolesnika s oštećenjem bubrega ili jetre.
Within the studied regimens of daclizumab beta 150 mg and 300 mg administered subcutaneous every 4 weeks in MS patients, there was no clear relationship between daclizumab beta exposure and clinical efficacy endpoints (ARR, T2 lesions and Gd-enhancing lesions) or safety endpoints of interest (serious infection status, moderate or severe cutaneous adverse reaction, and AST/ALT > 5 times the ULN). 
Unutar ispitivanih režima daklizumaba beta od 150 mg i 300 mg primijenjenih supkutano svaka 4 tjedna u bolesnika s MS-om, nije bilo jasnog odnosa između izloženosti daklizumabu beta i ishoda kliničke djelotvornosti (godišnje stope relapsa, lezije na T2-mjerenoj snimci i lezije imbibirane gadolinijem) ili ishoda sigurnosti od interesa (stanje ozbiljne infekcije, umjerene ili teške kožne nuspojave, i AST/ALT > 5 puta GGN).
• your skin or the whites of your eyes turn yellow 
• da su Vaša koža ili bjeloočnice požutjele
The causal relationship between daclizumab beta and sarcoidosis is considered possible. 
Uzročna povezanost između daklizumaba beta i sarkoidoze smatra se mogućom.
Sodium succinate, succinic acid, sodium chloride, polysorbate 80, water for injections 
Natrijev sukcinat, sukcinatna kiselina, natrijev klorid, polisorbat 80, voda za injekcije
• the pen has been dropped or is visibly damaged. 
• je brizgalica pala ili je vidljivo oštećena.
• the solution is any other colour than colourless to slightly yellow 
• je otopina bilo koje druge boje osim bezbojne do blago žute
Daclizumab beta is not expected to undergo renal elimination or metabolism by hepatic enzymes (see section 4.2). 
Ne očekuje se da se daklizumab beta eliminira putem bubrega ili metabolizira jetrenim enzimima (vidjeti dio 4.2).
Let your injection site dry on its own before injecting your dose. 
Pustite da se mjesto injiciranja samo osuši prije injiciranja doze.
The exact metabolic pathway for daclizumab beta has not been characterised. 
Točan metabolički put daklizumaba beta nije razjašnjen.
The active substance in Zinbryta is daclizumab beta. 
Djelatna tvar Zinbryte je daklizumab beta.
Daclizumab beta is not expected to undergo metabolism by hepatic enzymes such as CYP isoenzymes (see section 4.5). 
Ne očekuje se da se daklizumab beta metabolizira jetrenim enzimima kao što su CYP izoenzimi (vidjeti dio 4.5).
Cumulatively, 24 cases of colitis have been retrieved from clinical trials. 
U kliničkim ispitivanjima kumulativno su zabilježena 24 slučaja kolitisa.
There is also a plausible mechanism of action for the development of sarcoidosis due to the immunomodulatory effects of daclizumab beta and involvement of daclizumab beta in the origin of other immune-mediated events. 
Vjerojatan mehanizam djelovanja za razvoj sarkoidoze postoji i zbog imunomodulirajućih učinaka daklizumaba beta i uključenosti daklizumaba beta u nastanak drugih imunološki posredovanih događaja.
• Check that the Zinbryta medicine is colourless or slightly yellow (See Figure syringe if the liquid is cloudy, or has 
• Provjerite da je lijek Zinbryta bezbojan ili blago žut (vidjeti sliku E).
• The importance of detecting signs and symptoms which might indicate hepatic injury, and if any of these occur, to promptly contact their physician; 
• navesti važnost otkrivanja znakova i simptoma koji mogu ukazivati na oštećenje jetre, i ako se bilo što od toga pojavi, odmah se obratiti liječniku • podatke o bolesniku, potpis i datum
Following subcutaneous administration of daclizumab beta 150 mg every 4 weeks, steady-state serum daclizumab beta concentrations were achieved by the 4th dose and daclizumab beta accumulated to a level approximately 2.5-fold compared to a single dose. 
Nakon supkutane primjene daklizumaba beta od 150 mg svaka 4 tjedna, koncentracije daklizumaba beta u serumu u stanju dinamičke ravnoteže postignute su do 4. doze te se daklizumab beta akumulirao do razine približno 2,5 puta veće u usporedbi s jednom dozom.
Step 8: Disposing of the used Zinbryta Pre-filled Syringe 
9. korak: Odlaganje iskorištenih Zinbryta brizgalica
There is a plausible mechanism of action for the development of this colitis due to immunomodulatory properties of daclizumab beta and involvement of daclizumab beta in the origin of other immune-mediated events. 
Za razvoj tog kolitisa postoji vjerojatan mehanizam djelovanja zbog imunomodulirajućih svojstava daklizumaba beta i uključenosti daklizumaba beta u nastanak drugih imunološki posredovanih događaja.
In the DECIDE study subgroup analysis, there was a statistically significant reduction observed compared to interferon beta-1a (intramuscular) on ARR and the number of new or newly enlarging T2 hyperintense lesions across subgroups (gender, age, prior MS DMT therapy, and disease activity levels). 
postojalo je statistički značajno smanjenje u usporedbi s interferonom beta-1a (intramuskularno) za godišnju stopu relapsa i broj novih ili novoprogredirajućih hiperintenzivnih lezija na T2-mjerenoj snimci za sve podskupine (spol, dob, prethodno liječenje MS-a terapijom koja modificira tijek bolesti i razine aktivnosti bolesti).
Taking into account the PRAC Assessment Report on the PSUR(s) for daclizumab beta, the scientific conclusions of CHMP are as follows: 
(PSUR) za daklizumab beta, znanstveni zaključci CHMP-a su sljedeći: Sarkoidoza